Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling

Nucleic Acid Therapeutics

Volumn 21, Issue 5, 2011, Pages 299-314

  Rockey, William M ^a   Hernandez, Frank J ^a   Huang, Sheng You ^b,c,d,e   Cao, Song ^b,c,e   Howell, Craig A ^a   Thomas, Gregory S ^f   Liu, Xiu Ying ^a   Lapteva, Natalia ^g   Spencer, David M ^g   McNamara, James O ^a   Zou, Xiaoqin ^b,c,d,e   Chen, Shi Jie ^b,c,e   Giangrande, Paloma H ^a,f  

^a UNIVERSITY OF IOWA   (United States)

^b Departments of Physics and Astronomy   (United States)

^c University of Missouri   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; PROSTATE SPECIFIC ANTIGEN; RNA; RNA APTAMER A9; RNA APTAMER A9A; RNA APTAMER A9B; RNA APTAMER A9C; RNA APTAMER A9D; RNA APTAMER A9E; RNA APTAMER A9F; RNA APTAMER A9G; RNA APTAMER A9G.1; RNA APTAMER A9G.2; RNA APTAMER A9G.3; RNA APTAMER A9G.4(A); RNA APTAMER A9G.4(B); RNA APTAMER A9G.5; RNA APTAMER A9G.6; RNA APTAMER A9H; RNA APTAMER A9I; RNA APTAMER A9J; RNA APTAMER A9K; RNA APTAMER A9L; UNCLASSIFIED DRUG;

ALGORITHM; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; PRIORITY JOURNAL; RATIONAL RNA TRUNCATION; RNA BINDING; RNA STRUCTURE;

APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG DESIGN; ENZYME ASSAYS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE;

EID: 80054730117     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2011.0313     Document Type: Article

References (73)

1. ADLER, A., FORSTER, N., HOMANN, M., and GORINGER, H.U. (2008). Post-SELEX chemical optimization of a trypano-some-specific RNA aptamer. Comb. Chem. High Throughput Screen. 11, 16-23.
2. ARRAIANO, C.M., BARBAS, A., and AMBLAR, M. (2008). Characterizing ribonucleases in vitro examples of synergies between biochemical and structural analysis. Methods En-zymol. 447, 131-160.
3. BACICH,D.J.,PINTO,J.T.,TONG,W.P.,andHESTON,W.D. (2001). Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm. Genome 12, 117-123. (Pubitemid 32147666)
4. BAGALKOT, V., FAROKHZAD, O.C., LANGER, R., and JON, S. (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 45, 8149-8152. (Pubitemid 44974149)
5. BIESECKER, G., DIHEL, L., ENNEY, K., and BENDELE, R.A. (1999). Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42, 219-230. (Pubitemid 29322305)
6. BUFF, M.C., SCHAFER, F., WULFFEN, B., MULLER, J., POTZSCH, B., HECKEL, A., and MAYER, G. (2010). Dependence of aptamer activity on opposed terminal extensions: improvement of light-regulation efficiency. Nucleic Acids Res. 38, 2111-2118.
7. BURGSTALLER, P., KOCHOYAN, M., and FAMULOK, M. (1995). Structural probing and damage selection of citrulline-and arginine-specific RNA aptamers identify base positions required for binding. Nucleic Acids Res. 23, 4769-4776.
8. BURMEISTER, P.E., LEWIS, S.D., SILVA, R.F., PREISS, J.R., HORWITZ, L.R., PENDERGRAST, P.S., MCCAULEY, T.G., KURZ, J.C., EPSTEIN, D.M., WILSON, C., and KEEFE, A.D. (2005). Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. Chem. Biol. 12, 25-33. (Pubitemid 40118323)
9. BURMEISTER, P.E., WANG, C., KILLOUGH, J.R., LEWIS, S.D., HORWITZ, L.R., FERGUSON, A., THOMPSON, K.M., PEN-DERGRAST, P.S., MCCAULEY, T.G., KURZ, M., DIENER, J., CLOAD, S.T., WILSON, C., and KEEFE, A.D. (2006). 2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides 16, 337-351. (Pubitemid 46034477)
10. CAO, S., and CHEN, S.J. (2005). Predicting RNA folding thermodynamics with a reduced chain representation model. RNA 11, 1884-1897. (Pubitemid 41720037)
11. CAO, S., and CHEN, S.J. (2006). Free energy landscapes of RNA/RNA complexes: with applications to snRNA complexes in spliceosomes. J. Mol. Biol. 357, 292-312. (Pubitemid 43339332)
12. CAO, S., and CHEN, S.J. (2009). A new computational approach for mechanical folding kinetics of RNA hairpins. Biophys. J. 96, 4024-4034.
13. CAO, S., and CHEN, S.J. (2011). Physics-based de novo prediction of RNA 3D structures. J. Phys. Chem. B 115, 4216-4226.
14. CAO, S., FURTIG, B., SCHWALBE, H., and CHEN, S.J. (2010). Folding kinetics for the conformational switch between alternative RNA structures. J. Phys. Chem. B 114, 13609-13615.
15. CAO, Z., TONG, R., MISHRA, A., XU, W., WONG, G.C., CHENG, J., and LU, Y. (2009). Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed. Engl. 48, 6494-6498.
16. CASE, D.A., CHEATHAM, T.E., 3rd, DARDEN, T., GOHLKE, H., LUO, R., MERZ, K.M., JR., ONUFRIEV, A., SIMMER-LING, C., WANG, B., and WOODS, R.J. (2005). The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668-1688. (Pubitemid 43076180)
17. CHAKRAVARTHY, U., ADAMIS, A.P., CUNNINGHAM, E.T., JR., GOLDBAUM, M., GUYER, D.R., KATZ, B., and PATEL, M. (2006). Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related mac-ular degeneration. Ophthalmology 113, 1508, e1501-e1525.
18. CHEN, S.J. (2008). RNA folding: conformational statistics, folding kinetics, and ion electrostatics. Annu. Rev. Biophys. 37, 197-214.
19. CHU, T.C., TWU, K.Y., ELLINGTON, A.D., and LEVY, M. (2006). Aptamer mediated siRNA delivery. Nucleic Acids Res. 34, e73.
20. COLOMBATTI, M., GRASSO, S., PORZIA, A., FRACASSO, G., SCUPOLI, M.T., CINGARLINI, S., POFFE, O., NAIM, H.Y., HEINE, M., TRIDENTE, G., MAINIERO, F., and RAMARLI, D. (2009). The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One 4, e4608.
21. COSMI, B. (2009). ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr. Opin. Mol. Ther. 11, 322-328.
22. DARTY, K., DENISE, A., and PONTY, Y. (2009). VARNA: interactive drawing and editing of the RNA secondary structure. Bioinformatics 25, 1974-1975.
23. DASSIE, J.P., LIU, X.Y., THOMAS, G.S., WHITAKER, R.M., THIEL, K.W., STOCKDALE, K.R., MEYERHOLZ, D.K., MCCAFFREY, A.P., MCNAMARA, J.O., 2nd, and GIAN-GRANDE, P.H. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-ex-pressing tumors. Nat. Biotechnol. 27, 839-849.
24. DAVIS, M.I., BENNETT, M.J., THOMAS, L.M., and BJORK-MAN, P.J. (2005). Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. U. S. A. 102, 5981-5986. (Pubitemid 40594241)
25. DHAR, S., GU, F.X., LANGER, R., FAROKHZAD, O.C., and LIPPARD, S.J. (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 105, 17356-17361.
26. DHAR, S., KOLISHETTI, N., LIPPARD, S.J., and FAROKHZAD, O.C. (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 108, 1850-1855.
27. DYKE, C.K., STEINHUBL, S.R., KLEIMAN, N.S., CANNON, R.O., ABERLE, L.G., LIN, M., MYLES, S.K., MELLONI, C., HARRINGTON, R.A., ALEXANDER, J.H., BECKER, R.C., and RUSCONI, C.P. (2006). First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114, 2490-2497. (Pubitemid 44901522)
28. EIKELBOOM, J.W., ZELENKOFSKE, S.L., and RUSCONI, C.P. (2010). Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler. Thromb. Vasc. Biol. 30, 382-387.
29. ELLINGTON, A.D., and SZOSTAK, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822.
30. FAROKHZAD, O.C., JON, S., KHADEMHOSSEINI, A., TRAN, T.N., LAVAN, D.A., and LANGER, R. (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64, 7668-7672. (Pubitemid 39446893)
31. FLOEGE, J., OSTENDORF, T., JANSSEN, U., BURG, M., RA-DEKE, H.H., VARGEESE, C., GILL, S.C., GREEN, L.S., and JANJIC, N. (1999). Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 154, 169-179. (Pubitemid 29031624)
32. GILBERT, J.C., DEFEO-FRAULINI, T., HUTABARAT, R.M., HORVATH, C.J., MERLINO, P.G., MARSH, H.N., HEALY, J.M., BOUFAKHREDDINE, S., HOLOHAN, T.V., and SCHAUB, R.G. (2007). First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116, 2678-2686. (Pubitemid 350291240)
33. GRAGOUDAS, E.S., ADAMIS, A.P., CUNNINGHAM, E.T., JR., FEINSOD, M., and GUYER, D.R. (2004). Pegaptanib for neo-vascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816. (Pubitemid 40051904)
34. GREEN, L., WAUGH, S., BINKLEY, J.P., HOSTOMSKA, Z., HOSTOMSKY, Z., and TUERK, C. (1995). Comprehensive chemical modification interference and nucleotide substitution analysis of an RNA pseudoknot inhibitor to HIV-1 reverse transcriptase. J. Mol. Biol. 247, 60-68.
35. GU, F., ZHANG, L., TEPLY, B.A., MANN, N., WANG, A., RADOVIC-MORENO, A.F., LANGER, R., and FAROKHZAD, O.C. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U. S. A. 105, 2586-2591. (Pubitemid 351520557)
36. HEALY, J.M., LEWIS, S.D., KURZ, M., BOOMER, R.M., THOMPSON, K.M., WILSON, C., and MCCAULEY, T.G. (2004). Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 21, 2234-2246. (Pubitemid 40568437)
37. HERNANDEZ, F.J., KALRA, N., WENGEL, J., and VESTER, B. (2009). Aptamers as a model for functional evaluation of LNA and 2'-amino LNA. Bioorg. Med. Chem. Lett. 19, 6585-6587.
38. HICKE, B.J., STEPHENS, A.W., GOULD, T., CHANG, Y.F., LYNOTT, C.K., HEIL, J., BORKOWSKI, S., HILGER, C.S., COOK, G., WARREN, S., and SCHMIDT, P.G. (2006). Tumor targeting by an aptamer. J. Nucl. Med. 47, 668-678. (Pubitemid 46768469)
39. HUANG, Y., ECKSTEIN, F., PADILLA, R., and SOUSA, R. (1997). Mechanism of ribose 2'-group discrimination by an RNA polymerase. Biochemistry 36, 8231-8242. (Pubitemid 27297532)
40. HUANG, S.Y., and ZOU, X. (2008). An iterative knowledge-based scoring function for protein-protein recognition. Proteins 72, 557-579. (Pubitemid 351928512)
41. HUANG, S.Y., and ZOU, X. (2010). MDockPP: A hierarchical approach for protein-protein docking and its application to CAPRI rounds 15-19. Proteins 78, 3096-3103.
42. JELLINEK, D., GREEN, L.S., BELL, C., LYNOTT, C.K., GILL, N., VARGEESE, C., KIRSCHENHEUTER, G., MCGEE, D.P., ABESINGHE, P., PIEKEN, W.A., et al. (1995). Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34, 11363-11372.
43. KATILIUS, E., FLORES, C., and WOODBURY, N.W. (2007). Exploring the sequence space of a DNA aptamer using mi-croarrays. Nucleic Acids Res. 35, 7626-7635.
44. KAWAGUCHI, T., ASAKAWA, H., TASHIRO, Y., JUNI, K., and SUEISHI, T. (1995). Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5'-terminal with poly(ethylene glycol). Biol. Pharm. Bull. 18, 474-476.
45. KEEFE, A.D., PAI, S., and ELLINGTON, A. (2010). Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550.
46. KULARATNE, S.A., WANG, K., SANTHAPURAM, H.K., and LOW, P.S. (2009). Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 6, 780-789.
47. LAPIDUS, R.G., TIFFANY, C.W., ISAACS, J.T., and SLUSHER, B.S. (2000). Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 45, 350-354.
48. LIN, Y., QIU, Q., GILL, S.C., and JAYASENA, S.D. (1994). Modified RNA sequence pools for in vitro selection. Nucleic Acids Res. 22, 5229-5234.
49. LUPOLD, S.E., HICKE, B.J., LIN, Y., and COFFEY, D.S. (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029-4033. (Pubitemid 34791070)
50. MATHEWS, D.H. (2006). RNA secondary structure analysis using RNA structure. Curr. Protoc. Bioinform. Chapter 12, Unit 12.6.
51. MATHEWS, D.H., TURNER, D.H., and ZUKER, M. (2007). RNA secondary structure prediction. Curr. Protoc. Nucleic Acid Chem. Chapter 11, Unit 11.2.
52. MCNAMARA, J.O., 2nd, ANDRECHEK, E.R., WANG, Y., VILES, K.D., REMPEL, R.E., GILBOA, E., SULLENGER, B.A., and GIANGRANDE, P.H. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015. (Pubitemid 44215395)
53. MCNAMARA, J.O., KOLONIAS, D., PASTOR, F., MITTLER, R.S., CHEN, L., GIANGRANDE, P.H., SULLENGER, B., and GILBOA, E. (2008). Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest. 118, 376-386.
54. MONGELARD, F., and BOUVET, P. (2010). AS-1411, a guano-sine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther. 12, 107-114.
55. NEFF, C.P., ZHOU, J., REMLING, L., KURUVILLA, J., ZHANG, J., LI, H., SMITH, D.D., SWIDERSKI, P., ROSSI, J.J., and AK-KINA, R. (2011). An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4( + ) T cell decline in humanized mice. Sci. Transl. Med. 3, 66ra6.
56. NG, E.W., and ADAMIS, A.P. (2006). Anti-VEGF aptamer (pe-gaptanib) therapy for ocular vascular diseases. Ann. N.Y. Acad. Sci. 1082, 151-171. (Pubitemid 44955460)
57. PADILLA, R., and SOUSA, R. (1999). Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2'-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res. 27, 1561-1563. (Pubitemid 29206303)
58. PASTOR,F.,KOLONIAS,D.,GIANGRANDE,P.H.,and GILBOA, E.(2010). Inductionoftumourimmunitybytargeted inhibitionof nonsense-mediated mRNA decay. Nature, 465,227-230.
59. REESE, C.B. (2005). Oligo-and poly-nucleotides: 50 years of chemical synthesis. Org. Biomol. Chem. 3, 3851-3868. (Pubitemid 41640794)
60. RUCKMAN, J., GREEN, L.S., BEESON, J., WAUGH, S., GILLETTE, W.L., HENNINGER, D.D., CLAESSON-WELSH, L., and JANJIC, N. (1998). 2'-Fluoropyrimidine RNA-based ap-tamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556-20567. (Pubitemid 28377626)
61. RUSCONI, C.P., SCARDINO, E., LAYZER, J., PITOC, G.A., ORTEL, T.L., MONROE, D., and SULLENGER, B.A. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94. (Pubitemid 34987876)
62. SASSANFAR, M., and SZOSTAK, J.W. (1993). An RNA motif that binds ATP. Nature 364, 550-553. (Pubitemid 23273104)
63. SERRA, M.J., and TURNER, D.H. (1995). Predicting thermody-namic properties of RNA. Methods Enzymol. 259, 242-261.
64. SILVER, D.A., PELLICER, I., FAIR, W.R., HESTON, W.D., and CORDON-CARDO, C. (1997). Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81-85. (Pubitemid 27079448)
65. SOONTORNWORAJIT, B., ZHOU, J., SNIPES, M.P., BATTIG, M.R., and WANG, Y. (2011). Affinity hydrogels for controlled protein release using nucleic acid aptamers and complementary oligonucleotides. Biomaterials 32, 6839-6849.
66. THIEL, K.W., and GIANGRANDE, P.H. (2009). Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19, 209-222.
67. WATSON, S.R., CHANG, Y.F., O'CONNELL, D., WEIGAND, L., RINGQUIST, S., and PARMA, D.H. (2000). Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. An-tisense Nucleic Acid Drug Dev. 10, 63-75. (Pubitemid 30255590)
68. WONG, I., and LOHMAN, T.M. (1993). A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc. Natl. Acad. Sci. U. S. A. 90, 5428-5432. (Pubitemid 23176173)
69. XIAO, Z., JIANG, X., BECKETT, M.L., and WRIGHT, G.L., JR. (2000). Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. Protein Expr. Purif. 19, 12-21. (Pubitemid 30387889)
70. YAO, V., BERKMAN, C.E., CHOI, J.K., O'KEEFE, D.S., and BACICH, D.J. (2010). Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 70, 305-316.
71. ZHOU, J., LI, H., LI, S., ZAIA, J., and ROSSI, J.J. (2008). Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 16, 1481-1489.
72. ZHOU, J., SOONTORNWORAJIT, B., SNIPES, M.P., and WANG, Y. (2011). Structural prediction and binding analysis of hybridized aptamers. J. Mol. Recognit. 24, 119-126.
73. ZHOU, J., SWIDERSKI, P., LI, H., ZHANG, J., NEFF, C.P., AKKINA, R., and ROSSI, J.J. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 37, 3094-3109.